A New and Cost-Effective Approach to Risk Stratification for Children with Precursor B-Cell Acute Lymphoblastic Leukemia Based on Competing Outcomes

Hossein Bonakchi 1, Bentolhoda Kuhestani Dehaghi 2, Fatemeh Sadat Hosseini Baharanchi 3, Sayeh Parkhideh 4, Hamid Farhangi 5 and Ahmad reza baghestani 6.

1Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Hematology and Blood Banking, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Minimally Invasive Surgery Research Center, Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
4Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Department of Pediatrics Hematology and Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6Physiotherapy Research Center, Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Received 2021 August 17; Revised 2022 May 06; Accepted 2022 May 31.

Abstract

Background: Acute lymphoblastic leukemia (ALL) is a malignancy of the white blood cells characterized by its rapid and aggressive progress that needs immediate treatment. ALL could affect both adults and children. Various patient- and disease-related factors may be involved in ALL patients’ prognosis. Therefore, it is critical to identify important risk factors related to the competing outcomes of patients with ALL.

Objectives: This study aimed to stratify the risk of outcomes of children with precursor B-cell ALL using demographic characteristics, laboratory characteristics, and extramedullary diseases. To achieve this goal, we used the best competing risks model to make an appropriate decision for children’s treatment according to this classification.

Methods: In this retrospective cohort study, 393 patients with ALL were included. ALL with B cell origins (CD20, CD19, CD10, and CD22 positive markers) was differentiated using flow cytometry. Complete remission was defined by a lymphoblast count of less than 5% in the bone marrow, presence of no blasts in cerebrospinal fluid (CSF), as well as complete disappearance of clinical symptoms. Patients with ALL were treated based on Berlin-Frankfurt-Münster (BFM). Competing outcomes were first-relapse and non-relapse mortality, respectively. Risk factors affecting competing outcomes were assessed based on a fully specified sub-distribution model.

Results: Five-year estimates for overall survival and event free survival were 75% (95% CI: 69 - 79%) and 71% (95% CI: 66 - 75%), respectively. Five-year incidence rates for first-relapse and non-relapse mortality in children were 11.4% (95% CI: 8.32 - 15.16%) and 17.6% (95% CI: 13.98 - 21.67%), respectively. Moreover, according to the results, children with WBC > 50000, hemoglobin 8, and tumor lysis syndrome for the first-relapse outcome, and children with central nervous system (CNS) involvement and tumor lysis syndrome for the non-relapse mortality (NRM) outcome were considered as high-risk groups.

Conclusions: We found that extramedullary diseases could have a crucial role in the risk stratification of children with precursor B-cell ALL. Therefore, for a targeted and effective treatment of high-risk children, in addition to chemotherapy, using appropriate PI3K pathway inhibitors, JAK2 pathway inhibitors, and antibody-based immunotherapy is recommended to reduce minimal residual disease and, consequently, mortality rate.

Keywords: Precursor B-Cell ALL, Risk Stratification, First-Relapse, Non-relapse Mortality, Competing Risks

1. Background

Acute lymphoblastic leukemia (ALL), a heterogeneous hematological malignancy, is characterized by the proliferation of immature lymphoid blood cells in bone marrow (BM), peripheral blood (PB), and other organs. In the United States, the incidence rate of ALL is estimated 1.38 per 100,000 people per year (1). Regarding the incidence rate, about 5,930 new cases of ALL and 1,500 deaths from ALL were reported in 2019 (2). The median age of ALL diagnoses is 15 years (3); but in 55.4%, 28%, and 12.3% of patients, the diagnosis age is under 20 years, 45 years or older, and 65 years or older, respectively (4). ALL is the most common hematological malignancy in the pediatric population, as it ac-
counts for 75 - 80% of acute leukemia cases in this population. Among adults, ALL makes up to 20% of acute leukemia cases (5, 6).

In recent decades, the cure rate and survival outcomes have significantly improved in patients with ALL, specifically in children (7). Based on SEER database analysis, the five-year overall survival rate in pediatrics was reported 89% (7, 8). Remissions generally owe to better understanding of molecular genetics and pathogenesis of the disease, combination of treatment and risk (risk-adapted), emergence of new target factors, and use of allogeneic hematopoietic stem cell transplantation (Allo-HSCT).

Among children, B-cell lineage ALL is the most common form, accounting for 80% of cases (9). Certain factors concerning the patient and the malignancy could affect the prognosis of patients with ALL. Some of these factors include the patient's age, WBC count, genetic/cytogenetic/immunophenotypic subgroup, and CNS involvement, which are of great importance in investigating the risk and prognosis of ALL in children. In 1993, the children's oncology group (COG) and the children's cancer group (CCG) identified a set of risk criteria classified as high and standard risk (10). In children with precursor B-cell ALL, almost every clinical trial considers age and leukocyte count for risk stratification. Different cooperative groups have been associated with a combination of clinical, biological, and outcome variables to classify patients with precursor B-cell ALL in risk groups (11, 12).

2. Objectives

The present study aimed to evaluate the survival rate of children with precursor B-cell ALL and investigate the prognosis factors affecting their survival rate. Due to the limitations in genetic and cytogenetic data registry, we classified the risks of childhood precursor B-cell ALL using demographic characteristics, laboratory characteristics, and extramedullary diseases, and having considered the best competing risks model (13). Because of high treatment and medical equipment costs, this risk evaluation method could potentially be beneficial in developing and underprivileged countries.

3. Methods

In this retrospective cohort study, patients younger than 15 years old with ALL who received treatment from 2007 to 2016 in the Sheikh Hospital of Mashhad, Iran, were included. During this period, a total of 600 patients were evaluated originally at the start of the study. Patients with T-cell ALL and duplicate or incomplete clinical data were excluded from the study. Finally, 393 patients with precursor B-cell ALL were included in the analysis.

Initially, childhood ALL was diagnosed by direct smear sampling of BM stained with Giemsa that confirmed the presence of at least 20% of lymphoblasts. Using flow cytometry, the B-cell lineage ALL (with CD19, CD20, CD10, and CD22 cell surface markers) could be differentiated. Complete remission was defined as the disappearance of blasts in the CSF, BM lymphoblasts of under 5%, and complete absence of clinical symptoms. In this center, the treatment protocol for patients with ALL was based on Berlin-Frankfurt-Münster 2009 (14) therapy and could be modified according to the patients' physical conditions and response to the treatment protocol. Patients' demographics, laboratory results, and treatment procedure information were collected from clinical documents. We reported other information in another study (15). Patients' clinical manifestations were considered as prognostic variables. The cut-off point for platelet count was identified corresponding to a study by Daly (16).

Patients' baseline characteristics were reported descriptively. The end points of study were overall survival (OS), event-free survival (EFS), first relapse, and non-relapse mortality (NRM). OS and first-relapse were defined as the time of treatment until death from any cause and relapse, respectively. EFS duration was calculated as the interval from the date of treatment to the date of the last follow-up or of the first event. NRM included all deaths without relapse.

Kaplan-Meier method was used to estimate EFS and OS probabilities. NRM was a competing risk for the first relapse. Univariate and multiple analyses were performed using the Cox proportional hazards model for OS and EFS and the classical fully specified sub-distribution model (13) for first-relapse and NRM. Multiple model selection in Cox proportional hazards model was done with a backward method for selecting the features with the highest prognostic value.

Prognostic factors, including age, gender, WBC count, hemoglobin, platelet, extramedullary diseases such as CNS involvement, hemorrhage, mediastinal mass, rheumatoid symptoms, hepatosplenomegaly, and lymphadenopathy were assessed in ALL children.

The assessment of PH assumption was performed using score process plot and Kolmogorov-type supremum test in cox PH model (significant level = 0.05). ALL patients in precursor B-cell subtype were considered. Computations were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA). The significant levels for univariate and multiple analyses were considered as 0.20 (17-19) and 0.05, respectively.
4. Results

4.1. Patient Characteristics

A total of 393 children diagnosed with precursor B-cell ALL were included in this study. The demographic and prognostic factors of patients are shown in Table 1. The median age of patients was four years. Among the study population, 8.7%, 76.8%, and 14.5% were under one year old, 1-10 years, and older than 10 years, respectively. Also, 227 (57.8%) and 166 (42.2%) patients were males and females, respectively. Also, 11 (2.8%) patients had CNS involvement and 382 (97.2%) were without CNS involvement. WBC levels were below 50000 in 341 (86.8%) and above 50000 in 51 (13%) patients.

4.2. Overall and Event Free Surveys

The mean of follow-up time was 71 months. The five-year estimates for OS (CI) and EFS (CI) were 75% (95% CI: 69 - 79%) and 71% (95% CI: 66 - 75%), respectively (Figure 1A and B). Eighty-nine patients had died. Non-relapse mortality and first-relapse outcomes were reported in 67 and 40 patients, respectively.

4.3. Incidence of NRM and First-Relapse

The five-year incidence rate of the first-relapse and the NRM in children were 11.4% (95% CI: 8.32 - 15.16%) and 17.6% (95% CI: 13.98 - 21.67%), respectively (Figure 1C).

4.4. Univariate Analysis of Cox Proportional Hazards Model in B-Cell Patients

Children older than ten years had a significantly higher mortality rate (2.80 times) compared to children aged 1 - 10 years (HR = 2.86; 80% CI: 2.05 - 3.83; P-value ≤ 0.001). Children with hemoglobin levels > 8 had 40% lower mortality than those with hemoglobin 8, which was statistically significant (HR = 0.60; 80% CI: 0.45 - 0.79; P-value = 0.01). The mortality rate in children with CNS involvement was significantly higher (2.60 times) than those without CNS involvement (HR = 2.60; 80% CI: 1.44 - 4.69; P-value = 0.03). Children with tumor lysis syndrome had considerably lower OS than those without tumor lysis syndrome (HR = 5.70; 80% CI: 3.75 - 8.65; P-value ≤ 0.0001). The age of the children was significantly associated with EFS (P-value = 0.004). The first-relapse or mortality in children aged ten years was significantly higher (2.14 times) than those aged 1 - 10 years old (HR = 2.14; 80% CI: 1.58 - 2.90; P-value = 0.001). Children with a WBC count of > 50000 had 48% higher first-relapse or mortality compared to patients with a WBC count of 50000 (HR = 1.48; 80% CI: 1.06 - 2.06; P-value = 0.12). Hemoglobin level > 8 significantly improved EFS (HR = 0.68; 80% CI: 0.53 - 0.87; P-value = 0.04). CNS involvement significantly reduced EFS in children (HR = 2.19; 80% CI: 1.21 - 3.94; P-value = 0.08). Children with hemoglobin had a 38% higher first-relapse or mortality than those without hemoglobin, which was significant (HR = 1.38; 80% CI: 1.008 - 1.90; P-value = 0.18). Tumor lysis syndrome significantly increased first-relapse or mortality rate in children (HR = 4.25; 80% CI: 2.82 - 6.40; P-value ≤ 0.0001) (Table 2).

4.5. Multiple Analysis of Cox Proportional Hazards Model in B-Cell Patients

Patient’s age, CNS involvement, tumor lysis syndrome for OS, and tumor lysis syndrome for EFS were included in the final cox proportional hazard model (Table 2). The proportional hazards assumption based on score process plot and Kolmogorov-type supremum test for prognostic factors were established, and these models were validated. After controlling for the effect of other variables, children aged over ten years had significantly lower OS than children aged 1 - 10 years old (AHR = 2.08; 95% CI = 1.22 - 3.54; P-value = 0.007) (Figure 2A). Hemoglobin level >8 reduced mortality rate by 47% and increased OS (AHR = 0.53; 95% CI = 0.34 - 0.83; P-value = 0.005) (Figure 2B). Children with CNS involvement and tumor lysis syndrome had lower survival; these patients had 2.83 and 3.73 times higher mortality, respectively (AHRs = 2.83 and 3.73; 95% CIs = 1.02 - 7.84 and 1.70 - 8.19; P-values = 0.04 and 0.001) (Figure 2C and D). According to the multiple model for EFS, children with tumor lysis syndrome had 2.73 times higher mortality than those without tumor lysis syndrome (AHR=2.73; 95% CI = 1.26 - 5.89; P-value = 0.01) (Figure 2E).

4.6. Univariate Analysis of EFS Model in B-Cell Patients

In the presence of non-relapse mortality event, the hazard of incidence of first-relapse in children with a WBC count of > 50000 was significantly higher (2.18 times) than that of children with a WBC count of 50000 (SHR = 2.18; 80% CI: 1.34 - 3.54; P-value = 0.03). The hazard of the first-relapse in children with hemoglobin levels > 8 was significantly lower (42%) compared to children with hemoglobin level 8 (SHR = 0.58; 80% CI: 0.39 - 0.89; P-value = 0.10). Tumor lysis syndrome significantly increased the hazard of first-relapse in children by 4.19 times (SHR = 4.19; 80% CI: 2.29 - 7.68; P-value = 0.002). In the presence of first-relapse event, the hazard of incidence of non-relapse mortality was 34% lower in females than males, which was statistically significant (SHR = 0.66; 80% CI: 0.47 - 0.92; P-value = 0.01). CNS involvement and tumor lysis syndrome significantly increased the hazard of non-relapse mortality by 3.28 and 3.73 times, respectively (SHRs = 3.28, 3.53, and 3.73; 80% CIs = 1.82 - 5.92 and 2.98 - 9.51; P-values = 0.01 and 0.000) (Table 3).
## Table 1. Descriptive Analysis of Prognostic Factors in Precursor B-cell ALL Patients (N = 393)

| Characteristics            | Values a |
|----------------------------|----------|
| Age (y)                    |          |
| Below 1                    | 34 (8.7) |
| Between 1 - 10             | 302 (76.8) |
| Above 10                   | 57 (14.5) |
| Missing                    | 0 (0)    |
| Gender                     |          |
| Male                       | 227 (57.8) |
| Female                     | 166 (42.2) |
| Missing                    | 0 (0)    |
| WBC count                  |          |
| Below 50000                | 341 (86.8) |
| Above 50000                | 51 (13)  |
| Missing                    | 1 (0.3)  |
| Hemoglobin (mean ± SD)     |          |
|                           | 7.96 ± 2.53 |
| Missing                    | 0 (0)    |
| Platelet count             |          |
| Below 150000               | 315 (80.2) |
| Between 150000 - 400000    | 63 (16)  |
| Above 400000               | 15 (3.8) |
| Missing                    | 0 (0)    |
| CNS involvement            |          |
| Positive                   | 11 (2.8) |
| Negative                   | 382 (97.2) |
| Missing                    | 0 (0)    |
| Hemorrhagic                |          |
| Yes                        | 57 (14.5) |
| No                         | 338 (85.5) |
| Missing                    | 0 (0)    |
| Mediastinal mass           |          |
| Yes                        | 1 (0.3)  |
| No                         | 392 (99.7) |
| Missing                    | 0 (0)    |
| Rheumatoid signs           |          |
| Yes                        | 126 (32.1) |
| No                         | 267 (76.9) |
| Missing                    | 0 (0)    |
| Tumor lysis syndrome       |          |
| Yes                        | 17 (4.3)  |
| No                         | 376 (95.7) |
| Missing                    | 0 (0)    |
| Hepatosplenomegaly         |          |
| Yes                        | 167 (42.5) |
| No                         | 226 (57.5) |
| Missing                    | 0 (0)    |
| Lymphadenopathy            |          |
| Yes                        | 76 (19.3)  |
| No                         | 317 (80.7) |
| Missing                    | 0 (0)    |

a Values are expressed as No. (%) unless otherwise indicated.
Figure 1. Standard Kaplan-Meier (KM) curves and cumulative incidence curves for end points of the study

Figure 2. Adjusted OS and EFS curves based on multiple models
### Table 2. Univariate and Multiple Cox Proportional Hazards Models for OS and EFS in Precursor B-Cell ALL Patients

| Variables          | Overall Survival | Event Free Survival |
|--------------------|------------------|---------------------|
|                    | HR (95%CI) ^a    | P-Value ^b          | AHR ^c (95%CI) ^b | P-Value ^b | HR (95%CI) ^a | P-Value ^b | AHR2 (95%CI) ^b | P-Value ^b |
| Age (y)            |                  |                     |                    |            |                |            |                |            |
| 1-10               |                  |                     |                    |            |                |            |                |            |
| ≤ 1                | 1.43 (0.90 - 2.67)| 0.31                | 0.86 (0.39 - 1.89) | 0.71       | 1.36 (0.90 - 2.06) | 0.33      |
| > 10               | 2.80 (2.05 - 3.83)| < 0.0001            | 2.08 (1.22 - 3.54) | 0.007      | 2.14 (1.58 - 2.90) | 0.001     |
| Gender             |                  |                     |                    |            |                |            |                |            |
| Male               | 0.24             |                     |                    |            |                |            |                |            |
| Female             |                  |                     |                    |            |                |            |                |            |
| WBC count          |                  |                     |                    |            |                |            |                |            |
| 50000              | 1.36 (0.93 - 1.97)| 0.29                | 1.48 (1.06 - 2.06) | 0.12 ^d    |
| Hemoglobin         |                  |                     |                    |            |                |            |                |            |
| 8                  | 0.60 (0.45 - 0.79)| 0.01                | 0.53 (0.34 - 0.83) | 0.005 ^d   | 0.68 (0.53 - 0.87) | 0.04 ^d   |
| Platelet count     | 0.57             | 0.93                |                    |            |                |            |                |            |
| CNS involvement    | 0.03 ^d          | 0.04 ^d             | 0.08 ^d            |            |
| No                 |                  |                     |                    |            |                |            |                |            |
| Yes                | 2.60 (1.44 - 4.69)| 0.03                | 2.83 (1.02 - 7.84) | 0.04       | 2.19 (1.21 - 3.94) | 0.08      |
| Hemorrhagic        | 0.21             | 0.18 ^d             |                    |            |
| No                 |                  |                     |                    |            |                |            |                |            |
| Yes                | 1.39 (0.98 - 1.97)| 0.21                | 1.38 (1.008 - 1.90) | 0.18      |
| Mediastinal mass   | 0.98             | 0.97                |                    |            |                |            |                |            |
| No                 |                  |                     |                    |            |                |            |                |            |
| Yes                | 0 (0 - INF)      | 0.98                | 0 (0 - INF)        | 0.97      |
| Rheumatoid signs   | 0.23             | 0.52                |                    |            |                |            |                |            |
| No                 |                  |                     |                    |            |                |            |                |            |
| Yes                | 0.75 (0.55 - 1.02)| 0.23                | 0.87 (0.66 - 1.14) | 0.52      |
| Tumor lysis syndrome | < 0.0001 ^d      | 0.001 ^e            | < 0.0001 ^d        | 0.01 ^e   |
| No                 |                  |                     |                    |            |                |            |                |            |
| Yes                | 5.70 (3.75 - 8.65)| < 0.0001            | 3.73 (1.70 - 8.19) | 0.001      | 4.25 (2.82 - 6.40) | < 0.0001 | 2.73 (1.26 - 5.89) | 0.01      |
| Hepatosplenomegaly | 0.72             | 0.94                |                    |            |                |            |                |            |
| No                 |                  |                     |                    |            |                |            |                |            |
| Yes                | 0.92 (0.70 - 1.22)| 0.72                | 0.98 (0.76 - 1.26) | 0.94      |
| Lymphadenopathy    | 0.45             | 0.77                |                    |            |                |            |                |            |
| No                 |                  |                     |                    |            |                |            |                |            |
| Yes                | 1.21 (0.87 - 1.67)| 0.45                | 1.07 (0.78 - 1.45) | 0.77      |

^a Univariate. ^b Multiple. ^c Adjusted hazards ratio. ^d Significant at 0.20. ^e Significant at 0.05.

4.7. Multiple Analysis of EFS Model in B-Cell Patients

The effects of WBC, hemoglobin, and tumor lysis syndrome on the incidence of first-relapse were significant (Table 3). The results of the multiple model showed that the hazard of first-relapse in children with a WBC count of > 50000 was 2.94 times higher than those with a WBC count of 50000, while the effects of other variables were constant in the presence of non-relapse mortality event (ASHR = 2.94; 95% CI: 1.50 - 5.76; P-value = 0.001). Hemoglobin level > 8 reduced first-relapse incidence by 45% (ASHR = 0.55; 95% CI: 0.36 - 0.85; P-value = 0.01). The incidence of first-relapse in children with tumor lysis syndrome was 3.45 times higher than in patients without tumor lysis syndrome (ASHR = 3.45; 95% CI: 1.31 - 9.02; P-value = 0.01). The ef-
fects of CNS involvement and tumor lysis syndrome on the incidence of first-relapse were significant (Table 3). In the presence of non-relapse mortality event, while the effect of the other variable was held constant, the results showed that children with CNS involvement were three times more likely to have NRM than those without CNS involvement (ASHR = 3.01; 95% CI: 1.18 - 7.63; P-value = 0.02). Tumor lysis syndrome increased the hazard of NRM by 5.35 times (ASHR = 5.35; 95% CI: 2.19 - 13.05; P-value ≤ 0.001). In addition, in the presence of first-relapse in the multiple model, the relationship between gender and NRM outcome was not significant (P-value = 0.25) (Table 3). As can be seen in Figure 3A, children with WBC count of >50000, hemoglobin level 8, and tumor lysis syndrome had a five-year CIF higher than children without these features (71% vs. 15%) for the first-relapse outcome. These patients were considered as the high-risk group for the first-relapse outcome. Moreover, according to Figure 3B, children with CNS involvement and tumor lysis syndrome had much higher five-year CIF (95% vs. 17%) for the NRM outcome. These patients were considered as the high-risk group for NRM outcome.

5. Discussion

ALL is the most common pediatric malignancy accounting for 75 - 80% of acute leukemias in childhood. Although ALL is prevalent in different age groups of children with the incidence rate of 3-4 per 100,000 people, it is more common in children aged 2 - 5 years and slightly more frequent in males (20, 21). ALL is a heterogeneous disease associated with distinct subgroups. These subgroups are followed by various outcomes and have demonstrated substantial differences according to biological, cellular, and molecular characteristics, treatment response, and relapse risk. ALL is classified into different risk subgroups based on genetic, biological, and clinical features such as sex and age at diagnosis, immunophenotypic, cytogenetic, molecular, and early medullar response to induction therapy (22, 23).

ALL is likely to be associated with alterations in hematological disorders such as increased WBC count and decreased hemoglobin concentration, as well as serious clinical complications such as CNS involvement, tumor lysis syndrome, and hemorrhagic bleeding. The occurrence of any of these complications that might worsen the prognosis of patients and increase mortality rate in children clarifies the necessity of further treatments for managing the disease. In this regard, we investigated the patients using univariate and multiple statistical methods and examined the NRM and first-relapse outcomes to predict the risk of outcomes of patients and identify high-risk groups (20, 24).

Throughout the NRM analysis, it was found that patients with involvement of CNS and TLS could be classified as the high-risk group, as the estimated five-year NRM incidence in these patients was 95%. This finding indicates that in patients with simultaneous manifestations of CNS and TLS, the probability of death from any cause except relapse after five years would be about 95%. In patients with no involvement of CNS and TLS, however, the five-year NRM incidence probability was 17%. These patients, with a five-year death rate of 17% without evidence of relapse, could be classified as the low-risk group.

Moreover, the results of univariate analyses revealed a significant association between TLS/CNS involvement and OS and EFS rate, as these survival rates decreased in patients with CNS involvement and patients with TLS. The results of multiple analyses also showed a significant relationship between TLS/CNS involvement and OS rate, as well as a significant association between TLS and EFS.

The existence of risk factors at the time of ALL diagnosis, including T cell immunophenotype, hyperleukocytosis, high-risk cytogenetic abnormalities such as t (1; 19) and t (9; 22) translocations, and rearrangement of the mixed lineage leukemia (MLL, or KMT2A) gene, could be the predisposing factors for CNS involvement, which is accompanied by poor prognosis in patients. This clinical complication, thus, might raise heightened concerns over ALL prognosis, despite its good treatment response in 80 - 90% of cases (25-28).

TLS is another major clinical complication in patients with ALL, as this life-threatening oncological emergency is associated with a high mortality rate, kidney failure, seizure, and heart arrhythmia. These problems could explain the necessity of early diagnosis and management (24). Additionally, among numerous short- and long-term mortality predictors, acute kidney injury (AKI) is one of the most important clinical complications in patients with TLS. Due to the increased concentrations of uric acid, phosphate, potassium, and urea, homeostatic mechanisms might fail to remove these substances that cause clinical signs of TLS (29). Furthermore, the higher TLS incidence in highly proliferative and high tumor burden malignancies such as lymphoma and leukemia are probably contributed to the increased risk of worse outcomes. TLS prevention, therefore, contributes to the identification of high-risk patients who could probably benefit from close monitoring and initial prophylactic measures (30).

In this study, multiple analysis for the first-relapse showed that patients with a WBC count of > 50000, hemoglobin concentration < 8, and TLS had a first-relapse probability of 71% after five years. This recurrence probability emphasized the importance of early diagnosis and treatment in patients included in the high-risk group due
to presenting these symptoms at the same time. However, patients who did not show these parameters simultaneously were classified as the low-risk group with a first-relapse rate of 15% after five years.

Patients’ age and CNS/TLS involvement were significantly associated with OS. In this regard, in patients younger than one year and older than ten years, CNS involvement and TLS incidence were associated with lower OS, because, as described before, CNS involvement due to risk factors like molecular disorders and TLS incidence with serious clinical implications would include patients in high-risk group and correlates with poor prognosis. Moreover, we observed a significant relationship between patients’ age with OS and EFS, as children under one year and over ten years old showed lower OS and EFS. Similar studies have demonstrated a higher possibility of genetic abnormalities with poor prognosis in this age group, like BCR-ABL1 t(q34, q11.2), MLL gene rearrangement, and hypodiploidy (31, 32).

Chen et al. observed a poor outcome accompanied by molecular rearrangements on chromosome 11q23 in children younger than one year old (33). Another potential reason for the poor prognosis in these children might be related to their immature immune system. This happens due to inefficient immune system response to the tumor antigens, resulting in a dramatically low immune surveillance in this age group (34).

An increased risk of B-ALL relapse, on the other hand, has been contributed to the age over ten years old at diagnosis. Accordingly, the COG has recently determined the age over 13 years old at diagnosis as a very high-risk feature (35). In the COG’s CCG study, multimodal regimens in older patients caused three-year post-relapse survival of 35.4%, 14.7%, and 48.6% in children aged 10 - 15 years, > 16 years, and < 10 years old, respectively (36). Worse outcomes in older pediatrics and young adults suffering from B-ALL have also been reported in various studies (37). Poor chemotherapy compliance, many patients with unfavorable risk factors like Philadelphia (Ph+) chromosome (5 - 7%), and new rearrangements and mutations in IKAROUS,
Jak, and CRLF2 genes are examples of explanations for worse outcomes in older patients (38, 39). In addition, hyperdiploidy and favorable cytogenetic features like t(12;21) (p13,q22) result in TEL-AML1 fusion, which occur less frequently in this age group compared to younger children (40,41).

Several studies showed that iron deficiency and hypoxia in patients with anemia could reduce the treatment response and develop resistance to treatment, which is an unfavorable complication affecting poor prognosis in anemic patients (42).

It is essential to highlight that iron could cause cells protection against oxidative tissue damage by nitrogen oxide. Hemoglobin deficiency in anemic patients could therefore lead to tissue damage and related complications. On the other hand, low hemoglobin levels at diagnosis is associated with more advanced disease (43). In this regard, in our study, univariate analysis indicated that the OS rate would decrease in patients with lower hemoglobin level (<8). The univariate analysis also showed decreased EFS and first-relapse rate in patients with WBC count of >50,000. Also, this study confirmed that a high WBC count (>50,000) is associated with decreased EFS rate, as well as increased relapse and death risk.

Previous studies reported that patients with severe leukocytosis at diagnosis are associated with complications such as bulky tumor mass, mediastinal enlargement, hepatosplenomegaly, and lymphadenopathy, which are usually related to unfavorable chromosomal translocations t(4;11) and t(9;22) (44). Leukocytosis is associated with decreased blood flow, blood stasis in capillaries, leukemic cells aggregation, micro thrombosis, the release of toxic granules from cells into the peripheral blood, vascular endothelial damage, oxygen consumption by leukocytes, and tissue invasion. In this regard, the increase in WBC count could be attributed to the lower EFS and first-relapse rate, which was also confirmed in our study (45).

In the current study, a significant relationship between gender and NRM was detected, such that males with ALL had a higher risk of NRM compared to females. One responsible factor is XY chromosomal instability mediating abnormal cell proliferation and more biologically aggressive leukemia in males. Testosterone hormone may also give rise to the worse prognosis in males.

5.1. Conclusion

In this study, we determined the risk in children with ALL to select appropriate treatment strategies for each risk group during induction therapy, consolidation therapy, and maintenance therapy, and evaluated treatment response and the minimal residual disease. Accordingly, hyper-CVAD chemotherapy [hyperfractionated cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone] is suggested for low-risk patients. However, the treatment of high-risk patients is based on chemotherapy plus clinical trials related to this group, such as PI3K pathway and JAK2 pathway inhibitors and antibody-based immunotherapy. This could potentially help low-risk patients benefit from treatments with low chemotherapy drug toxicity, and high-risk patients or patients resistant to standard treatment benefit from the best treatment choice and reduced minimal residual disease and mortality rate in this group (46-48).

Acknowledgments

The authors would like to thank the Pediatric Hematology and Oncology Group of Mashhad University of Medical Sciences, Iran that provided the information required for this research.

Footnotes

Authors’ Contribution: Study concept and design, H.B, B.K.H, E.S.H.B, S.P, H.F, and A.R.B; Acquisition of data, H.B, B.K.H, E.S.H.B, S.P, H.F, and A.R.B; Analysis and interpretation of data, H.B, B.K.H, E.S.H.B, S.P, H.F, and A.R.B; Drafting of the manuscript, H.B, B.K.H, and S.P; Critical revision of the manuscript for important intellectual content, H.B, B.K.H, S.P, and H.F; Statistical analysis, H.B, E.S.H.B, and A.R.B; Administrative, technical, and material support, H.B, B.K.H and H.F; Study supervision, H.B, B.K.H, and A.R.B.

Conflict of Interests: Authors declare no conflict of interests.

Data Reproducibility: It was not declared by the authors.

Ethical Approval: This study was approved by Shahid Beheshti University of Medical Sciences (ethics code: IR.SBMU.RETECH.REC.1399.304; link: ethics.research.ac.ir/ProposalCertificate.php?id=140009)

Funding/Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2015: Leukemia, annual incidence rates (acute lymphocytic leukemia). Maryland, USA: National Cancer Institute; 2018, [cited 2021]. Available from: https://seer.cancer.gov/archive/csr/1975_2015/
2. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2019;69[1]:7-34. doi: 10.3322/caac.21551. PubMed: 30620402.
3. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2015: Overview, median age at diagnosis. Maryland, USA: National Cancer Institute; 2018, [cited 2021]. Available from: https://seer.cancer.gov/csr/1975_2015/.
4. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2015: Overview, age distribution of incidence cases by site. Maryland, USA: National Cancer Institute; 2018, [cited 2021].
5. Esparza SD, Sakamoto KM. Pediatric leukemia—acute lymphoblastic leukemia. MedGenMed. 2005;7(7):231. [PubMed: 16369328]. [PubMed Central: PMC1638186].
6. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005;80(11):1557-27. doi: 10.4065/80.11.1557. [PubMed: 16295031].
7. Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. 4. Springer Nature; 2014. doi: 10.1038/srep04427.
8. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):4408-11. doi: 10.1182/blood-2008-06-164863. [PubMed: 18974370].
9. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(5):535-48. doi: 10.1056/NEJMra023001. [PubMed: 15071128].
10. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynor P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(3):338-4. doi: 10.1200/JCO.1996.14.3.338. [PubMed: 8558995].
11. Schultz KR, Pullen DJ, Sather HN, Shuster JI, Devidas M, Borowitz Mj, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood. 2007;109(3):926-35. doi: 10.1182/blood-2006-01-024729. [PubMed: 17003180]. [PubMed Central: PMC1785141].
12. Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 5-001. Blood. 2012;119(14):5494-9. doi: 10.1182/bloodadvances.2012081584. [PubMed: 23807291].
13. Ge M, Chen MH. Bayesian inference of the fully specified subdistribution model for survival data with competing risks. Lifetime Data Anal. 2012;18(3):319-63. doi: 10.1007/s10985-012-9229-1. [PubMed: 22484596]. [PubMed Central: PMC3734515].
14. Chang J, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, et al. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2006;49(12):1298-307. doi: 10.1080/10428190600717732. [PubMed: 19905277]. [PubMed Central: PMC2444806].
15. Saeedi A, Baghestani A, Bonakchi H, Khosravi A, Farhangi H, Badiei S, et al. Determining the Survival Rate in Children with ALL in the Northeast of Iran via Competing Risks Approach. Middle East J Cancer. 2020;9(1):1-9. doi: 10.30476/mejc.2020.81284.0.
16. Daly ME. Determinants of platelet count in humans. Haematologica. 2011;96(1):310-3. doi: 10.3324/haematol.2010.35287. [PubMed: 21093429]. [PubMed Central: PMC3012758].
17. Hosmer DW, Lemeshow S, May SA. Applied survival analysis: regression modeling of time-to-event data. 2nd ed. New Jersey, USA: John Wiley & Sons Inc; 2008. doi: 10.1002/9780470725089.
18. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3(1):7. doi: 10.1186/1753-1075-3-47. [PubMed: 19087314]. [PubMed Central: PMC2310055].
19. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1999;149(9):3125-37. doi: 10.1093/oxfordjournals.aje.a015030. [PubMed: 990056].
20. Peters C, Locatelli F, Bader P. Acute lymphoblastic leukemia in children and adolescents. In: Carreras E, Dufour C, Mohy M, Kroger N, editors. The EBMT Handbook. Cham, Switzerland: Springer; 2019. p. 539-45. doi: 10.1007/978-3-030-02278-5_72.
21. Board PPTE IPCIS. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®). Bethesda (MD), USA: National Cancer Institute (US); 2020.
cent and young adult population. Ther Adv Hematol. 2020;11:1–25. doi: 10.1177/2040620720903531. [PubMed: 32077170]. [PubMed Central: PMC6997963].

38. Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, et al. JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia. Oncotarget. 2017;8(52):89923–38. doi: 10.18632/oncotarget.21027. [PubMed: 29163799]. [PubMed Central: PMC5685720].

39. Roberts KG, Mullighan CG. The Biology of B-Progenitor Acute Lymphoblastic Leukemia. Cold Spring Harb Perspect Med. 2020;10(7). doi: 10.1101/cshperspect.a034835. [PubMed: 31653664]. [PubMed Central: PMC7328455].

40. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6). e577. doi: 10.1038/bcj.2017.51. [PubMed: 28665449]. [PubMed Central: PMC5520400].

41. Chen Z, Sun Y, Xie W, Wang SA, Hu S, Li S, et al. Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia? Cancer Med. 2019;8(9):4093–9. doi: 10.1002/cam4.2255. [PubMed: 3173486]. [PubMed Central: PMC6675728].

42. Pattnaik J, Kayal S, Dubashi B, Basu D, Vinod KV, Nandeesh H, et al. Profile of anemia in acute lymphoblastic leukemia patients on maintenance therapy and the effect of micronutrient supplementation. Support Care Cancer. 2020;28(2):731–8. doi: 10.1007/s00520-019-04862-6. [PubMed: 3014344].

43. Goldberg JM, Silverman LR, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21(19):3616–22. doi: 10.1200/JCO.2003.10.186. [PubMed: 14512392].

44. Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Felix FH, de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37(4):223–9. doi: 10.1016/j.r barric.2015.03.009. [PubMed: 26904244]. [PubMed Central: PMC4597101].

45. Gamal Abdul H. Acute Leukemia Clinical Presentation. In: Guenova M, Balatzenko G, editors. Leukemia. London, UK: IntechOpen; 2013. doi: 10.5772/53531.

46. Lenk L, Alsadeq A, Schewe DM. Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data. Cancer Metastasis Rev. 2020;39(1):173–87. doi: 10.1007/s10555-020-09848-2. [PubMed: 31970588]. [PubMed Central: PMC7098933].

47. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(1):81–112. doi: 10.6004/jnccn.2020.0001. [PubMed: 3190389].

48. Sanchez VE, Nichols C, Kim HN, Gang EJ, Kim YM. Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2019;20(2). doi: 10.3390/ijms20020412. [PubMed: 30669372]. [PubMed Central: PMC6358866].
Table 3. Univariate and Multiple EFS Model for First-Relapse and NRM Simultaneously in Precursor B-Cell ALL Patients

| Variable                  | Relapse                  |             | Multiple Analysis |             |
|---------------------------|--------------------------|-------------|-------------------|-------------|
|                           | SHR $^a$ (90% CI)        | P-Value     | ASHR $^b$ (95% CI)| P-Value     |
| **Relapse**               |                          |             |                   |             |
| Age (y)                   | 0.27                     |             |                   |             |
| 1 - 10                    | -                        | -           |                   |             |
| ≤ 1                       | 1.45 (0.84 - 2.95)       | 0.34        |                   |             |
| > 10                      | 1.59 (0.96 - 2.60)       | 0.23        |                   |             |
| Gender                    | 0.38                     |             |                   |             |
| Male                      | -                        | -           |                   |             |
| Female                    | 1.32 (0.87 - 2.00)       | 0.38        |                   |             |
| **WBC count**             |                          |             |                   |             |
| 50000                     | -                        | -           |                   |             |
| 500000                    | 2.18 (1.34 - 3.54)       | 0.03        | 2.94 (1.50 - 5.76)| 0.001       |
| **Hemoglobin**            |                          |             |                   |             |
| 8                         | -                        | -           |                   |             |
| 8                         | 0.58 (0.39 - 0.89)       | 0.10        |                   |             |
| **Platelet count**        |                          |             |                   |             |
| 150000 - 4000000          | -                        | -           |                   |             |
| 150000                    | 0.64 (0.39 - 1.05)       | 0.25        |                   |             |
| 400000                    | 1.51 (0.64 - 3.56)       | 0.53        |                   |             |
| **CNS involvement**       | 0.51                     |             |                   |             |
| No                        | -                        | -           |                   |             |
| Yes                       | 0.40 (0.06 - 2.39)       | 0.51        |                   |             |
| **Hemorrhagic**           | 0.34                     |             |                   |             |
| No                        | -                        | -           |                   |             |
| Yes                       | 1.45 (0.87 - 2.40)       | 0.34        |                   |             |
| **Mediastinal mass**      | 0.91                     |             |                   |             |
| No                        | -                        | -           |                   |             |
| Yes                       | 0.72 (0.03-36.22)        | 0.91        |                   |             |
| **Rheumatoid signs**      | 0.99                     |             |                   |             |
| No                        | -                        | -           |                   |             |
| Yes                       | 0.99 (0.64 - 1.53)       | 0.99        |                   |             |
| **Tumor lysis syndrome**  | 0.002 $^c$              | 0.01 $^d$  |                   |             |
| No                        | -                        | -           |                   |             |
| Yes                       | 4.19 (2.29 - 7.68)       | 0.002       | 3.45 (1.31 - 9.02)| 0.01        |
| **Hepatosplenomegaly**    | 0.51                     |             |                   |             |
| No                        | -                        | -           |                   |             |
| Yes                       | 0.81 (0.53 - 1.22)       | 0.51        |                   |             |
| **lymphadenopathy**       | 0.51                     |             |                   |             |
| No                        | -                        | -           |                   |             |
| Yes                       | 0.64 (0.26 - 1.54)       | 0.51        |                   |             |
| **NRM**                   |                          |             |                   |             |
| **Age (y)**               | 0.23                     |             |                   |             |
| 1 - 10                    | -                        | -           |                   |             |
| ≤ 1                       | 1.20 (0.73 - 2.95)       | 0.55        |                   |             |
| > 10                      | 2.38 (0.66 - 3.40)       | 0.47        |                   |             |
| Gender                    | 0.11 $^e$               | 0.25        |                   |             |
| Male                      | -                        | -           |                   |             |
| Female                    | 0.66 (0.47 - 0.92)       | 0.11        | 0.74 (0.45 - 1.23)| 0.25        |
| **WBC count**             | 0.49                     |             |                   |             |
| 500000                    | -                        | -           |                   |             |
| 5000000                   | 1.28 (0.80 - 2.03)       | 0.49        |                   |             |
| Condition                  | 0.01 | 0.02 |
|----------------------------|------|------|
| Hemoglobin 0.62            | 5.33 | 5.35 |
| 8                          | -    | -    |
| 8                          | 0.88 (0.64 - 1.21) | 0.62 |
| Platelet count 0.29        | -    | -    |
| 150000 - 400000            | -    | -    |
| 1500000                    | 1.45 (0.89 - 2.36) | 0.32 |
| 4000000                    | 0.54 (0.13 - 2.13) | 0.57 |
| CNS involvement 0.01       | 3.28 | 3.01 |
| No                         | -    | -    |
| Yes                        | 1.34 (0.89 - 2.02) | 0.35 |
| Hemorrhagic 0.35           | -    | -    |
| No                         | -    | -    |
| Yes                        | 0.65 (0.01 - 25.34) | 0.87 |
| Mediastinal mass 0.87      | -    | -    |
| No                         | -    | -    |
| Yes                        | 0.58 (0.58 - 1.16) | 0.47 |
| Rheumatoid signs 0.47      | -    | -    |
| No                         | -    | -    |
| Yes                        | 0.82 (0.01 - 25.34) | 0.47 |
| Tumor Lysis Syndrome 0.000 | 5.33 | 5.35 |
| No                         | -    | -    |
| Yes                        | 5.31 (2.98 - 9.51) | 0.000 |
| Hepatosplenomegaly 0.88    | -    | -    |
| No                         | -    | -    |
| Yes                        | 1.03 (0.75 - 1.42) | 0.88 |
| Lymphadenopathy 0.59       | -    | -    |
| No                         | -    | -    |
| Yes                        | 1.17 (0.80 - 1.70) | 0.59 |

Subhazard ratio.
Adjusted Subhazard ratio.
Significant at 0.20.
Significant at 0.05.